Shai Shimony
@ShaiShimony
Followers
234
Following
673
Statuses
376
Physician @DanaFarber Medical Oncolgy & Leukemia team. Taking care of people is not a job, it’s a passion and a way of living
Brookline, MA
Joined August 2015
RT @DanaFarber: Marlise Luskin, MD, MSCE (@LuskinMarlise) explores novel approaches to ABL1 inhibition to improve outcomes and minimize tox…
0
6
0
RT @oncodaily: Biology and Management of NPM1 Mutated AML - @ShaiShimony
@LuskinMarlise
#Cancer #OncoDaily #Med…
0
2
0
RT @lane_andy: Updated website for the #BPDCN Center @DanaFarber, importantly adding my wonderful faculty colleagues who have built their o…
0
3
0
A comprehensive, up-to-date and clinically relevant review on NPM1-mutated #AMLsm. Led by Evan_Chen, @LuskinMarlise and Richard_Stone, this is trully a clinical pearl for clinicians @DanaFarberNews @AjHematology
2
18
76
Our commentary is out in @AjHematology! "Sharpening the Tools to Get the Edge on Leukemia" with Jacqueline_Garcia on @n_gangat Mayo clinic model ( for #AMLsm treated with HMA+VEN.
0
3
11
RT @MGooptu: Great experience collaborating with Moses for this review!! Star mentees make our jobs easy :) @haematognomist
0
2
0
RT @DanaFarberNews: In a study published in @JAMAOnc, @DanaFarber researchers, led by Gregory Abel, MD, find care after donor stem cell tra…
0
10
0
Excited to share our new manuscript co-authored by @DanaFarber BMT mentors Dr. Gooptu (@MGooptu) and Dr. Soiffer: How I Treat AML relapse after allogeneic HCT: No one-size fits all approach to this challenging situation, learned a ton writing it!
1
1
8
RT @Eddie_Cliff: Huge congrats to my friend @NicoGagelmann and colleagues for their work just out in @NEJM! They show that patients with…
0
14
0
Today at #ASH24, @ShaiShimony presented findings from a Phase 3 AML trial, which reveals CPX-351 improves survival for AML-MR patients. Hear from the @DanaFarber researchers.
0
0
1
It was a pleasure to discuss about our recent findings in #BPDCN prognostication. Would like to thank my collegues and mentors @lane_andy @LuskinMarlise and others @DanaFarber. Published by @VJHemOnc
0
4
9
RT @MPN_Hub: CONGRESS | #ASH24 | PRESENTATION Nico Gagelmann @NicoGagelmann, University Medical Center Hamburg, aimed to develop a uniform…
0
10
0
RT @LeukDocJZ: Great presentation by @ShaiShimony showing that the benefit of CPX vs 7+3 is driven by MDS-related mutations. Unfortunately,…
0
7
0
RT @AML_Hub: CONGRESS | #ASH24 | PRESENTATION @ShaiShimony @DanaFarber highlights results from a post hoc analysis of the phase III CPX-351…
0
7
0
RT @DanaFarberNews: Today at #ASH24, @ShaiShimony presented findings from a Phase 3 AML trial, which reveals CPX-351 improves survival for…
0
3
0
RT @AML_Hub: CONGRESS | #ASH24 | PRESENTATION Richard M Stone @DanaFarber discusses findings from the 10-year follow up of the phase III CA…
0
6
0
RT @lane_andy: Here are the top line data for overall survival (OS) using the new #BPDCN 3-parameter prognostic model by @ShaiShimony. Favo…
0
4
0
RT @emmamgroarke: A nice commentary in this issue of @BloodJournal for our paper looking at the role of #ClonalHematopoiesis in #TBD from @…
0
18
0